A. CLAS	SIFICATION OF SUBJECT MATTER		•			
IPC7: 4	A61K 31/4025,31/155,31/195,C	07D207/26,211/98,401/	12,403/12,			
	215/00, A61P 19/00,37/00,21/	00				
	to International Patent Classification (IPC) or to both n	ational classification and IPC				
	OS SEARCHED	· · · · · · · · · · · · · · · · · · ·				
	decumentation searched (classification system followed b	y classification symbols)				
 						
	tion searched other than minimum documentation to th	s extent that such documents are included i	n the fields searched			
-						
· Exectronic o	late base consulted during the international search (nam	e of data base and, where practicable, searc	h terms used)			
EPO-IN	TERNAL, WPI DATA, PAJ, STN-CAPLUS					
C. DOCL	MENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.			
A	WO 9963929 A2 (ADVANCED MEDICINI 16 December 1999 (16.12.1999	E, INC.), 9), formula I	1-16			
	=-	·				
A	WO 9912912 A1 (YUHAN CORPORATION (18.03.1999), formula I	1-16				
A	WO 9316992 A1 (MERRELL DOW PHAR) 2 Sept 1993 (02.09.1993), for	1-16				
A	EP 0325397 A1 (YAMANOUCHI PHARM 26 July 1989 (26.07.1989),	0325397 A1 (YAMANOUCHI PHARMACEUTICAL CO. LTD.), 26 July 1989 (26.07.1989), formula I				
X Furth	er documents are listed in the continuation of Box	C. X See patent family annex				
	categories of cited documents:	"T" later document published after the inte	ernational filing date or priority			
to be or	"A" document defining the general state of the art which is not considered to be of particular relevance to be of particular relevance to be of particular relevance to be of particular relevance.					
"L" docume	"E" earlier application or patent but published on or after the international filing date "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive					
dited to special "O" docume	died to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance: the claimed invention cannot considered to involve an inventive step when the document is					
"P" docume	ent published prior to the international filing date but later than bity date claimed	combined with one or more other such being obvious to a person skilled in the document member of the same patent	e art			
Date of the	e actual completion of the international search	Date of mailing of the international				
13 May	13 May 2005 17 -05- 2005					
Name and	mailing address of the ISA/	Authorized officer				
Swedish.	Patent Office . , 8-102 42 STOCKHOLM	FERNANDO FARIETA/ELY				
	No. +46 8 666 02 86	Telephone No. + 46 8 782 25 00				
Form PCT/IS	SA/210 (second sheet) (January 2004)					

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	J. Am. Chem. Soc., Volume 117, 1995, James S. Nowick et al, "Molecular Scaffolds. 2. Intramolecular Hydrogen Bonding in 1,2-Diaminoethande Diureas", pages 89-99, see the whole document	1-16
	·	
	•	
	•	
	•	
	•	
	•	
	·	
		·
		•

			•	••			
МO	9963929	A2	16/12/1999	AU	764401 B	21/08/2003	
	•			AU	4426399 A	30/12/1999	
			•	AU	4426699 A	30/12/1999	
•	•			AU	4428899 A	30/12/1999	
•				AU	4430599 A	30/12/1999	
				AU	4543699 A	30/12/1999	
				AU	4543799 A	30/12/1999	
				AU	4543899 A 4551699 A	30/12/1999 30/12/1999	
	•		9	UA UA	4551699 A 4551799 A	30/12/1999 30/12/1999	
				UA	4551799 A 4551899 A	30/12/1999	
			-	AU	4674599 A	30/12/1999	
				AU	4677199 A	30/12/1999	
		•		AU	4677399 A	30/12/1999	
				AU	4818099 A	30/12/1999	
				CA	2316999 A	16/12/1999	
				· CA	2318547 A	16/12/1999	
				CA	2319080 A	16/12/1999	
				CA	2319120 A	16/12/1999	•
				CA	2319474 A	16/12/1999	
,			•	CA	2319477 A	16/12/1999 16/12/1999	
				CA CA	2319495 A 2319761 A	16/12/1999 16/12/1999	
1				CA CA	2319761 A 2320241 A	16/12/1999 16/12/1999	
[•	CA	2320241 A 2320290 A	16/12/1999 16/12/1999	
[CA -	2320290 A 2321162 A	16/12/1999	
Ĭ				CA	2321162 A 2321166 A	16/12/1999	
Į				CA	2321100 A 2321190 A	16/12/1999	
				CA	2321274 A	16/12/1999	
İ				EP	0989857 A	05/04/2000	
				EP	1003541 A	31/05/2000	
				EP	1005356 A	07/06/2000	
1				EP	1083894 A	21/03/2001	-
]				EP ED	1083919 A	21/03/2001	
				EP EP	1083920 A 1085845 A	21/03/2001 28/03/2001	•
}				EP EP	1085845 A 1085846 A	28/03/2001 28/03/2001	
				EP EP	1085846 A 1085861 A	28/03/2001 28/03/2001	
				EP EP	1085861 A 1085891 A	28/03/2001 28/03/2001	
1.				EP	1085893 A	28/03/2001	
				EP	1085055 A	28/03/2001	
1				EP	1124528 A	22/08/2001	-
				EP .	1143991 A	17/10/2001	
				JP	2002517422 T	18/06/2002	
•				JP	2002517423 T	18/06/2002	
				JP	2002517458 T	18/06/2002	
				JP N7	2002517465 T	18/06/2002	
			•	NZ SG	505979 A	26/09/2003 22/05/2001	
l .				SG SG	80631 A 90053 A	22/05/2001 23/07/2002	
				SG SG	90053 A 106036 A	23/07/2002 30/09/2004	
]				US Se	106036 A 5888001 A	30/09/2004 30/03/1999	
				US US	5888001 A 6288234 B	30/03/1999 11/09/2001	
		•		US	6355810 B	12/03/2001	
				US	6395724 B	28/05/2002	
!				_	•	-,	
1							

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No. PCT/SE 2005/000054

MO	9963929	A2	16/12/1999	US	6566509 B	20/05/2003
				US	20020028943 A	07/03/2002
				US	20030176670 A	18/09/2003
			•	US	20040023290 A	05/02/2004
		•	•	MO	9963937 A	16/12/1999
				MO	9963939 A	16/12/1999
	•			MO		
				WO		16/12/1999
•				MO	9963988 A	16/12/1999
					9963994 A	16/12/1999
			•	₩O	9964032° A	16/12/1999
•				MO	9964033 A	16/12/1999
			•	WO	9964037 A	16/12/1999
				WO	9964047 A	16/12/1999
				WO	9964048 A	16/12/1999
				WO	9964049 A	16/12/1999
	•			WO	9964051 A	16/12/1999
•				MO	9964054 A	16/12/1999
				ZA	200004086 A	10/08/2001
				ZA	200004558 A	30/11/2001
				ZA	200004559 A	02/04/2002
	•			AT	198105 T	15/12/2000
				AU	4996693 A	03/03/1994
				DE	69329751 D.T	12/04/2001
				DK	606469 T	17/04/2001
				EP	0606469 A.B	20/07/1994
				GR	3035461 T	31/05/2001
				JP	7503090 T	30/03/1995
				NO	941141 A	20/05/1994
				ÜS	6090726 A	18/07/2000
WO	9912912	A1	18/03/1999	AU	9005398 A	29/03/1999
WO	9316992	A1	02/09/1993	AT	165345 T	15/05/1998
•				AU	663925 B	26/10/1995
•				AU	3481893 A	13/09/1993
•				CA	2130360 A,C	21/08/1993
				DE	69318136 D,T	
				EP		22/10/1998
				SE		07/12/1994
				ES	· · · · · · · · · · · · · · · · · · ·	61 /67 /1 000
-					2115756 T	01/07/1998
				IL	104780 A	30/10/1998
				JP	3309104 B	29/07/2002
		•	•	JP	7504190 T	11/05/1995
		•		KR	275843 B	15/12/2000
				MX	9300836 A	01/09/1993
				NZ	249032 A	25/09/1996
				US	5359131 A	25/10/1994
				ZA	9301035 A	17/09/1993
					7 St 10 St 10 to sport and all all all all all all all all all al	

Form PCT/ISA/210 (patent family annex) (January 2004)



			•		Λ	
EP	0325397	A1	26/07/1989	SE	0325397 T3	
_,				AT	93230 T	15/09/1993
	·			AU	627439 B	27/08/1992
				AU	2866989 A	05/10/1989
				CN	1021819 B,C	18/08/1993
				CN	1034538 A	09/08/1989
				DE	68908425 D,T	23/12/1993
				DK	22289 A	21/07/1989
				ES	2059714 T	16/11/1994
	•		•	HU	50116 A	28/12/1989
				HŨ	207843 B	28/06/1993
				ΙE	63207 B,L	05/04/1995
				ĪĒ	890179 L	20/07/1989
				JP	1119455 U	14/08/1989
				JP	2117651 A	02/05/1990
x				MX	9203657 A	
						31/07/1992
				US	5091419 A	25/02/1992
				US	5166429 A	24/11/1992
				US	5227492 A	13/07/1993
				US	5384425 A	24/01/1995

AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No. PCT/SE2005/000054

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: 14-16 because they relate to subject matter not required to be searched by this Authority, namely: Claims 14-16 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)




International application No.
PCT/SE 2005/000054

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention relates to novel diurea derivatives that block intracellular signal transduction and thereby inhibit the production of pro-inflammatory cytokines, especially interleukin-2 (IL-2) and/or induce apoptosis in activated T-cells. It further discloses such a compound for use as a medicament, the use of said compound for the manufacturing of a medicament for the treatment of immune disorders which benefit from inhibition of production of IL-2 and other pro-inflammatory cytokines and/or induction of apoptosis in activated T-cells, a pharmaceutical composition comprising said compound and a method of treatment comprising administration of a pharmaceutically effective amount of said compound.

A compound of the general formula I



Form PCT/ISA/210 (continuation of first sheet (3)) (January 2004)